Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study

The Lancet Infectious Diseases

Volumn 18, Issue 8, 2018, Pages 884-893

  Sivapalasingam, Sumathi ^a   Kamal, Mohamed ^a   Slim, Rabih ^a   Hosain, Romana ^a   Shao, Weiping ^a   Stoltz, Randall ^b   Yen, Joseph ^a   Pologe, Laura G ^a   Cao, Yuan ^a   Partridge, Michael ^a   Sumner, Giane ^a   Lipsich, Leah ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b 206 Carnegie Center   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; PLACEBO; REGN 3470 3471 3479; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EBOLAVIRUS; ELIMINATION RATE CONSTANT; FEMALE; FIRST IN HUMAN STUDY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; IMMUNOGENICITY; INFESTATION; INJECTION SITE PAIN; MALE; MYALGIA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; POLYURIA; PRESYNCOPE; PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNITED STATES; VIRAL UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; EBOLA HEMORRHAGIC FEVER; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MIDDLE AGED; PATIENT SAFETY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; EBOLAVIRUS; FEMALE; GLYCOPROTEINS; HEADACHE; HEALTHY VOLUNTEERS; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; UNITED STATES; YOUNG ADULT;

EID: 85048770052     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(18)30397-9     Document Type: Article

References (15)

1. De Clercq, E, Ebola virus (EBOV) infection: therapeutic strategies. Biochem Pharmacol 93 (2015), 1–10.
2. WHO Team, Agua-Agum, J, Allegranzi, B, et al. After Ebola in west Africa—unpredictable risks, preventable epidemics. N Engl J Med 375 (2016), 587–596.
3. Brainard, J, Hooper, L, Pond, K, Edmunds, K, Hunter, PR, Risk factors for transmission of Ebola or Marburg virus disease: a systematic review and meta-analysis. Int J Epidemiol 45 (2016), 102–116.
4. Schieffelin, JS, Shaffer, JG, Goba, A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 371 (2014), 2092–2100.
5. de La Vega, MA, Wong, G, Kobinger, GP, Qiu, X, The multiple roles of sGP in Ebola pathogenesis. Viral Immunol 28 (2015), 3–9.
6. Pascal, KE, Dudgeon, D, Trefry, JC, et al. Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates. J Infect Dis, 2018 published online May 31. DOI: 1093/infdis/jiy285.
7. Murphy, AJ, Macdonald, LE, Stevens, S, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA 111 (2014), 5153–5158.
8. FDA, Guidance for industry toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. https://www.fda.gov/downloads/BiologicsBloodVaccines/ucm091977, 2018. (Accessed 11 June 2018)
9. Lim, JJ, Deng, R, Derby, MA, et al. Two phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza A virus monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob Agents Chemother 60 (2016), 5437–5444.
10. Davey, RT Jr, Nordwall, J, Proschan, MA, Prevail, IIST, Trial of ZMapp for Ebola virus infection. N Engl J Med 376 (2017), 700–701.
11. Pallesen, J, Murin, CD, de Val, N, et al. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol, 1, 2016, 16128.
12. Murin, CD, Fusco, ML, Bornholdt, ZA, et al. Structures of protective antibodies reveal sites of vulnerability on Ebola virus. Proc Natl Acad Sci USA 111 (2014), 17182–17187.
13. de La Vega, MA, Caleo, G, Audet, J, et al. Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest 125 (2015), 4421–4428.
14. Bah, EI, Lamah, MC, Fletcher, T, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med 372 (2015), 40–47.
15. WHO, Notes for the record. Consultation on monitored emergency use of unregistered and investigational interventions for Ebola virus disease (EVD). http://www.who.int/emergencies/ebola/MEURI-Ebola.pdf, May 17, 2018. (Accessed 5 June 2018)